Ralimetinib

DB11787InvestigationalSmall molecule

Ralimetinib has been used in trials studying the treatment of Postmenopausal, Advanced Cancer, Adult Glioblastoma, Fallopian Tube Cancer, and Metastatic Breast Cancer, among others.

Mechanism: Pharmacologically active on Mitogen-activated protein kinase 14
Curator reviewed
Formula / weight: C₂₄H₂₉FN₆ · 420.536 g/mol (avg)
Code names: LY-2228820 · LY2228820 FREE BASE

Resolves to

Compound

UNII73I34XW4HDCAS862505-00-8ChEMBLCHEMBL2364626PubChem11539025

Structure

InChIKeyXPPBBJCBDOEXDN-UHFFFAOYSA-NSMILESCC(C)(C)CN1C(N)=NC2=CC=C(N=C12)C1=C(NC(=N1)C(C)(C)C)C1=CC=C(F)C=C1

Targets

Q16539MAPK14

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ralimetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account